Jean‐François Prost

1.6k total citations
47 papers, 1.3k citations indexed

About

Jean‐François Prost is a scholar working on Radiology, Nuclear Medicine and Imaging, Molecular Biology and Cardiology and Cardiovascular Medicine. According to data from OpenAlex, Jean‐François Prost has authored 47 papers receiving a total of 1.3k indexed citations (citations by other indexed papers that have themselves been cited), including 14 papers in Radiology, Nuclear Medicine and Imaging, 11 papers in Molecular Biology and 8 papers in Cardiology and Cardiovascular Medicine. Recurrent topics in Jean‐François Prost's work include Monoclonal and Polyclonal Antibodies Research (13 papers), Chronic Lymphocytic Leukemia Research (6 papers) and Blood Pressure and Hypertension Studies (4 papers). Jean‐François Prost is often cited by papers focused on Monoclonal and Polyclonal Antibodies Research (13 papers), Chronic Lymphocytic Leukemia Research (6 papers) and Blood Pressure and Hypertension Studies (4 papers). Jean‐François Prost collaborates with scholars based in France, Belgium and United States. Jean‐François Prost's co-authors include J.-P. Vilaine, Arnaud Pillon, Philip Janiak, Joël Vian, Catherine Thollon, J.‐L. PEGLION, Virginie Molle, Laurent Kremer, Christine Girard-Blanc and Nicolas Gangneux and has published in prestigious journals such as Journal of Clinical Oncology, Blood and Journal of Molecular Biology.

In The Last Decade

Jean‐François Prost

47 papers receiving 1.2k citations

Peers

Countries citing papers authored by Jean‐François Prost

Since Specialization

Citations

This map shows the geographic impact of Jean‐François Prost's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Jean‐François Prost with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Jean‐François Prost more than expected).

Fields of papers citing papers by Jean‐François Prost

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Jean‐François Prost. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Jean‐François Prost. The network helps show where Jean‐François Prost may publish in the future.

Co-authorship network of co-authors of Jean‐François Prost

This figure shows the co-authorship network connecting the top 25 collaborators of Jean‐François Prost. A scholar is included among the top collaborators of Jean‐François Prost based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Jean‐François Prost. Jean‐François Prost is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Murlentamab, a Low Fucosylated Anti-Müllerian Hormone Type II Receptor (AMHRII) Antibody, Exhibits Anti-Tumor Activity through Tumor-Associated Macrophage Reprogrammation and T Cell Activation 2021 ·Cancers ·(unknown), (unknown), Thibault Allain, Olivier Dubreuil, G. R. Noel, Laurence Preisser, (unknown), Lydie Cassard, (unknown), (unknown), Bernard Pipy, Pascale Jeannin, Jean‐François Prost, Jean‐Marc Barret, Agnès Coste	7
2	ITCH-dependent proteasomal degradation of c-FLIP induced by the anti-HER3 antibody 9F7-F11 promotes DR5/caspase 8-mediated apoptosis of tumor cells 2019 ·Cell Communication and Signaling ·Christophe Le Clorennec, Yassamine Lazrek, Olivier Dubreuil, (unknown), Christel Larbouret, (unknown), Marie‐Alix Poul, Jean‐Marc Barret, Jean‐François Prost, André Pèlegrin, Thierry Chardès	13
3	Quantification of HER1, HER2 and HER3 by time-resolved Förster resonance energy transfer in FFPE triple-negative breast cancer samples 2019 ·British Journal of Cancer ·Alexandre Ho-Pun-Cheung, Hervé Bazin, Florence Boissière‐Michot, Caroline Mollévi, Joëlle Simony-Lafontaine, (unknown), Jean‐Pierre Bleuse, Thierry Chardès, Jean‐François Prost, André Pèlegrin, William Jacot, Gérard Mathis, Evelyne Lopez‐Crapez	12
4	Neuregulin 1 Allosterically Enhances the Antitumor Effects of the Noncompeting Anti-HER3 Antibody 9F7-F11 by Increasing Its Binding to HER3 2017 ·Molecular Cancer Therapeutics ·Christophe Le Clorennec, Hervé Bazin, Olivier Dubreuil, Christel Larbouret, Charline Ogier, Yassamine Lazrek, Véronique Garambois, Marie‐Alix Poul, Philippe Mondon, Jean‐Marc Barret, Gérard Mathis, Jean‐François Prost, André Pèlegrin, Thierry Chardès	13
5	Anticorps monoclonaux à usage thérapeutique : spécificités du développement clinique, évaluation par les agences, suivi de la tolérance à long terme 2012 ·Therapies ·Gilles Paintaud, Marine Diviné, Philippe Lechat, Martine Bagot, (unknown), Anne d’Andon, (unknown), Thierry Lecomte, Soyi Liu-Léage, Daniel Olive, Pascal Piedbois, (unknown), (unknown), Jean‐François Prost, Gilles Thibault, (unknown)	2
6	Monoclonal Antibodies for Therapeutic Use: Specific Characteristics of Clinical Development, Evaluation by the Agencies, and Long-term Monitoring of Safety 2012 ·Therapies ·Gilles Paintaud, Marine Diviné, Philippe Lechat, Martine Bagot, (unknown), Anne d’Andon, (unknown), Thierry Lecomte, Soyi Liu-Léage, Daniel Olive, Pascal Piedbois, (unknown), (unknown), Jean‐François Prost, Gilles Thibault, (unknown)	2
7	Analysis of CD16+CD56dim NK cells from CLL patients: evidence supporting a therapeutic strategy with optimized anti-CD20 monoclonal antibodies 2010 ·Leukemia ·Magali Le Garff‐Tavernier, (unknown), Christophe de Romeuf, Christophe Parizot, Charles‐Antoine Dutertre, Élise Chapiro, F Davi, Patrice Debré, Jean‐François Prost, Jean‐Luc Teillaud, Hélène Merle‐Béral, Vincent Vieillard	46
8	Prophylaxis and Therapy for Chikungunya Virus Infection 2009 ·The Journal of Infectious Diseases ·Thérèse Couderc, Nassirah Khandoudi, Marc Grandadam, (unknown), Nicolas Gangneux, Sébastien Bagot, Jean‐François Prost, Marc Lecuit	193
9	Protein PknE, a novel transmembrane eukaryotic-like serine/threonine kinase from Mycobacterium tuberculosis 2003 ·Biochemical and Biophysical Research Communications ·Virginie Molle, Christine Girard-Blanc, Laurent Kremer, Patricia Doublet, Alain J. Cozzone, Jean‐François Prost	42
10	Corrections et addition au Catalogue des plantes vasculaires de la chaîne jurassienne 2002 ·Jean‐François Prost	1
11	Convivialités électives : Entretien 2000 ·Érudit (Université de Montréal) ·(unknown), Jean‐François Prost	1
12	Inactivation of isocitrate dehydrogenase kinase/phosphatase by 5′‐[p‐(fluorosulfonyl)benzoyl]adenosine is not due to the labeling of the invariant lysine residue found in the protein kinase family 1998 ·European Journal of Biochemistry ·(unknown), Jean‐Michel Jault, Michel Jaquinod, Didier Négre, Jean‐François Prost, (unknown), Jc Cortay	10
13	New N.alpha.-Guanidinobenzoyl Derivatives of Hirudin-54-65 Containing Stabilized Carboxyl or Phosphoryl Groups on the Side Chain of Phenylalanine-63 1994 ·Journal of Medicinal Chemistry ·Christophe Thurieau, Serge Simonet, Joseph A. Paladino, Jean‐François Prost, Tony J. Verbeuren, Jean‐Luc Fauchère	17
14	S 14297, a novel selective ligand at cloned human dopamine D3 receptors, blocks 7-OH-DPAT-induced hypothermia in rats 1994 ·European Journal of Pharmacology ·(unknown), Valérie Audinot, Jean‐Michel Rivet, Alain P. Gobert, Joël Vian, Jean‐François Prost, Michael Spedding, Jean-Louis Péglion	48
15	Effect of Tertatolol on Glomerular Hemodynamics in the Normal Munich-Wistar Rat 1989 ·American Journal of Hypertension ·Francis B. Gabbai, O. W. Peterson, Jean‐François Prost, Roland C. Blantz	2
16	The Tertatolol International Multicenter Study (T.I.M.S.): Predicting Factors of an Efficient Therapy 1989 ·American Journal of Hypertension ·(unknown), (unknown), (unknown), Jean‐François Prost, Michel E. Safar	1
17	Acute Effects of Tertatolol and Nadolol on Systemic and Renal Hemodynamics in Patients with Essential Hypertension 1988 ·American Journal of Hypertension ·J P Degaute, Robert Naeije, Marc Abramowicz, Marc Leeman, André Schoutens, Jean‐François Prost	7
18	Preserved Renal Perfusion During Beta Blockade by Tertatolol with and without Cyclooxygenase Inhibition in Normal Humans 1988 ·The Journal of Clinical Pharmacology ·(unknown), Marc Leeman, (unknown), (unknown), Jean‐François Prost, Robert Naeije	6
19	PROLONGED BETA BLOCKADE DUE TO TERTATOLOL: A COMPARATIVE STUDY WITH PROPRANOLOL AND ATENOLOL 1987 ·Fundamental and Clinical Pharmacology ·Pierre Desché, A. Cournot, (unknown), Jean‐François Prost, (unknown)	1
20	Numerical treatment of cardiac diseases using optimal control theory 1986 ·Mathematical Modelling ·Y. Cherruault, (unknown), (unknown), Jean‐François Prost	3

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact